Back to today’s briefing

Story perspectives

Gibraltar Explores Mounjaro for Obesity Amid High Demand

1/18/2025

34 3

Summary

Story summary

The Gibraltar Health Authority is taking a closer look at Mounjaro (tirzepatide) for obesity treatment after trials revealed it leads to more significant weight loss than Wegovy. Meanwhile, NICE is preparing for a gradual rollout that could span 12 years due to overwhelming demand, with eligibility set for those with a BMI of 35kg/m² or higher and related health concerns.

1 of 1

Story summary

The Gibraltar Health Authority is taking a closer look at Mounjaro (tirzepatide) for obesity treatment after trials revealed it leads to more significant weight loss than Wegovy. Meanwhile, NICE is preparing for a gradual rollout that could span 12 years due to overwhelming demand, with eligibility set for those with a BMI of 35kg/m² or higher and related health concerns.